Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tak-664

Phase 3

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary Immunodeficiency Diseases (PID)Not yet recruiting

Primary Immunodeficiency Diseases (PID)Phase 3

Not yet recruiting

Timeline

Expected Milestones

Q4 2027

ApprovedNot yet recruiting

Primary Immunodeficiency Diseases (PID)

NCT07794735

Clinical

Trials by Indication[1]

Primary Immunodeficiency Diseases (PID)1 trial

Multicenter, Prospective, Open-Label Trial to Evaluate PK, Safety, and Tolerability of TAK-664 in IG Treatment-Naïve Participants With Primary Immunodeficiency Diseases

Not yet recruiting· Takeda logo

Takeda·Approved·NCT07794735·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tak-664. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tak-664. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Takeda

Related News